固定水平频率阈值测试用于耳毒性监测
研究评估了一种类似Békésy的固定水平频率阈值(FLFT)技术的重复性和准确性,该测试可在不到一分钟内确定最高可听频率。29名正常听力受试者(年龄23-35岁,平均28岁)至少4次完成FLFT和固定频率听力计测试,结果显示FLFT的组间变异平均RMSD为0.05±0.05倍频程,无学习效应,与固定频率听力计确定的最高可听频率平均绝对差为0.03倍频程,两者差异无统计学意义(p=0.12)。FLFT约需30秒完成,而固定频率听力计SRO约需4.5分钟,传统耳毒性听力评估需20-25分钟。
要点
- FLFT测试重复性良好,组间变异平均RMSD为0.05±0.05倍频程。
- FLFT与固定频率听力计确定的最高可听频率平均绝对差为0.03倍频程,差异无统计学意义(p=0.12)。
- FLFT约30秒完成,适合自动化和自我管理,可能用于快速、准确的噪声耐受性耳毒性监测。
核心结论
- 类似Békésy的FLFT测试重复性在1/12倍频程内(测试程序中的1步长)。
- FLFT与固定频率听力计在80 dB SPL下确定的最高可听频率一致性良好。
- FLFT测试适合自动化和自我管理,可能实现快速、准确、噪声耐受的耳毒性和高频听力监测。
研究设计与样本
- 研究纳入29名正常听力受试者(20名女性,9名男性),年龄23至35岁(平均28岁)。
- 受试者在至少3周内至少4次完成两种不同的自动听力计测试。
- 测试在单壁隔声室内使用Sennheiser HDA-200耳机和基于笔记本电脑的计算机系统完成。
主要发现
- FLFT组间变异平均RMSD为0.05±0.05倍频程。
- FLFT测试未显示学习效应[F(3,78)=0.7;p=0.6]。
- SRO固定频率听力计所有频率的总体组间变异为5.8 dB(范围2.7至9.9 dB),在临床可接受的测试-重测变异(10 dB)内。
- 固定频率听力计与FLFT确定的最高可听频率之间的平均绝对差为0.03倍频程。
- FLFT与固定频率听力计在80 dB SPL下确定的最高可听频率差异无统计学意义(p=0.12)。
关键数值与推荐
- SRO定义为最高可听频率及以下按1/6倍频程步进的七个频率。
- FLFT测试在每个测试时段以80 dB SPL进行。
- FLFT重复性计算为与首次测试时段的均方根差。
- FLFT准确性计算为与固定频率听力计插值至80 dB SPL水平确定的最高可听频率之差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hearing loss from ototoxicity is often most pronounced at high frequencies. To improve patient monitoring and compliance, high-frequency testing methods should be short and easy to administer. We evaluated the repeatability and accuracy of a Békésy-like, fixed-level frequency threshold (FLFT) technique. This test takes less than a minute and could provide a rapid and effective way to determine the highest audible frequency. We hypothesized the FLFT test would be repeatable in normal-hearing subjects, and accurate when compared with Békésy fixed-frequency audiometry in the sensitive region for ototoxicity (SRO). DESIGN: Twenty-nine normal-hearing subjects (20 females, 9 males) performed 2 different automated audiometry tests at least 4 times over a period of no less than 3 weeks. Ages ranged from 23 to 35 years (average = 28 years). Subjects completed testing under Sennheiser HDA-200 headsets. Initial fixed-frequency audiometry thresholds were obtained at frequencies ranging from 0.5 to 20 kHz to identify each subject's highest audible frequency, which was used to determine the SRO. The SRO was defined as the seven frequencies at and below the highest audible frequency in 1/6-octave steps. These frequencies were monitored with fixed-frequency audiometry. At each session, the FLFT test was administered at 80 dB SPL. Subjects used a Békésy-style tracking method to determine the frequency threshold. All testing was completed in a sound booth (single wall, Industrial Acoustics Company) using a computerized, laptop-based, system. FLFT repeatability was calculated as the root mean square difference from the first test session. FLFT accuracy was calculated as the difference from the highest audible frequency determined from fixed-frequency audiometry interpolated to 80 dB SPL level. RESULTS: The FLFT average RMSD for intersession variability was 0.05 ± 0.05 octaves. The test showed no learning effect [F(3,78) = 0.7; p = 0.6]. The overall intersession variability for SRO fixed-frequency audiometry thresholds at all frequencies was within clinically acceptable test-retest variability (10 dB) at 5.8 dB (range 2.7 to 9.9 dB). The SRO fixed-frequency audiometry therefore served as a repeatable basis of comparison for accuracy of the FLFT test. The mean absolute difference between the fixed-frequency audiometry and FLFT-determined highest audible frequency was 0.03 octaves. The FLFT and the highest audible frequency via fixed-frequency audiometry at 80 dB SPL were not different statistically (p = 0.12). The FLFT took approximately 30 seconds to complete, compared with approximately 4.5 min for fixed-frequency audiometry SRO and 20 to 25 min for a traditional ototoxic audiometric assessment. CONCLUSIONS: The Békésy-style FLFT was repeatable within 1/12 octave (1 step size in the testing procedure). The FLFT agreed well with the highest audible frequency determined via fixed-frequency audiometry at 80 dB SPL. The FLFT test is amenable to automatic and self-administration and may enable quick, accurate, noise-tolerant ototoxicity, and high-frequency hearing monitoring.
引用
- Rieke CC, Clavier OH, Allen LV, et al. Fixed-Level Frequency Threshold Testing for Ototoxicity Monitoring. Ear Hear. 2017. PMID: 28362673. doi:10.1097/AUD.0000000000000433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。